HIV-1 Infection
Conditions
Keywords
HIV-1 infection, Therapeutic Vaccines, HTI, Antiretroviral Treatment Interruption (ATI), Viral control
Brief summary
The AELIX-002 trial has been conducted on a cohort of individuals who started cART within the first 6 months after the primary VIH infection, thus increasing the likelihood of observing a certain rate of post-treatment controls (PTC), regardless of treatment efficacy. Although the kinetics of HIV rebound should allow observing differences between placebo and control regarding the post treatment controls rate in case of efficacy of the IMPs, assessing the length and determinants of a post-intervention control (PIC) (i.e., associated with vaccination) beyond 24 weeks is crucial for developing a curative approach to HIV infection. In this regard, an extension of the ATI phase for those individuals with pVL less than 2,000 copies/mL after 24 weeks of ATI in the AELIX-002 offers an unique research opportunity to better understand relevant aspects of the mechanisms involved in the different phenotypes of a PIC and PTC.
Detailed description
The AELIX-002 trial has been conducted on a cohort of individuals who started cART within the first 6 months after the primary VIH infection, thus increasing the likelihood of observing a certain rate of post-treatment controls (PTC), regardless of treatment efficacy. Although the kinetics of HIV rebound should allow observing differences between placebo and control regarding the post treatment controls rate in case of efficacy of the IMPs, assessing the length and determinants of a post-intervention control (PIC) (i.e., associated with vaccination) beyond 24 weeks is crucial for developing a curative approach to HIV infection. In this regard, an extension of the ATI phase for those individuals with pVL less than 2,000 copies/mL after 24 weeks of ATI in the AELIX-002 offers an unique research opportunity to better understand relevant aspects of the mechanisms involved in the different phenotypes of a PIC and PTC. This trial will enrol participants of the AELIX-002 clinical trial regardless of whether they received vaccines or placebo, who reach 24 weeks of ATI with pVL \<2,000 cop/ml and are willing to remain off cART. After accepting participation, subjects will undergo a one-year extension \[48 weeks\] of ATI monitoring (total duration of ATI envisioned will be of 72 weeks \[24 weeks in AELIX-002 study + 48 weeks in current study\]), followed by 24 weeks of safety follow-up after cART is resumed. The primary objective of this study is to assess the safety and durability of viral control after AELIX-002 clinical trial intervention beyond 6 months of ATI. Furthermore, the study will collect biological samples to be stored for further investigational studies.
Interventions
BIOLOGICALVaccine + extension of the ATI period
During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI\_extension trial, ATI will be extended for 48 weeks.
OTHERPlacebo + extension of the ATI period
During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI\_extension trial, ATI will be extended for 48 weeks.
Sponsors
Aelix Therapeutics
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
AELIX-002 was a double-blind clinical trial. During ATI\_extension, AELIX-002 will be unblinded and allocation will be disclosed to both participants and investigators.
Intervention model description
Participants of the AELIX-002 clinical trial were randomly allocated to one of the following arms: * Vaccine: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. * Placebo: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. ATI\_extension will keep allocation from AELIX-002 for a separate description of the results.
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Participants of the AELIX-002 clinical trial at week 24 of ATI: 1. Willing to continue the ATI up to 1 year. 2. With pVL \<2,000 copies/ml at week 24 of ATI on the AELIX-002 study. 3. CD4 count ≥350 cells/mm3 at week 24 of ATI on the AELIX-002study. 4. Willing to comply with the measures to prevent HIV transmission and reinfection required by the protocol. 5. Available for follow-up for the planned duration of the ATI period of this study. 6. Willing to accept blood draws and collect stool at time points specified in the Schedule of Procedures. 7. If heterosexually active female; using an effective method of contraception (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner1) during the ATI and until her pVL is \<50 copies/ml after cART resumption. 8. If heterosexually active male; using an effective method of contraception (anatomical sterility in self) or agree on the use of an effective method of contraception by his partner (hormonal contraception, intra-uterine device (IUD), or anatomical sterility1) during the ATI and until his pVL is \<50 copies/ml after cART resumption. 9. Not willing to donate blood during the study. 10. Participants who understand the information provided, in the opinion of the investigator.
Exclusion criteria
1- Pregnancy or breastfeeding. 2\. History or clinical manifestations of any physical or psychiatric disorder which could impair the subject's ability to complete the study. 3\. Any other current or prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study. 4\. Active hepatitis B or C at week 24 of ATI on the AELIX-002 study. 5\. Risk of HIV transmission (i.e. repeated STI during the AELIX-002 ATI period or reported unprotected anal sex).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time off cART | From ATI start to week 72 | Time off cART, defined as time to cART resumption from ATI start. |
| Percentage of participants with viral remission | week 72 | Percentage of participants with viral remission, defined as plasma viral load (pVL) \<50 copies/ml at 72 weeks after start of ATI. |
| Percentage of participants with viral control | week 72 | Percentage of participants with viral control, defined as a pVL \<2,000 copies/ml at 72?weeks after start of ATI. |
| Time to viral detection | up to 72weeks after start of ATI | Time to viral detection up to 72 weeks after start of ATI, defined as the time from ATI start to first occurrence of detectable pVL (≥50 copies/ml). |
| Time to viral rebound | up to 72 weeks after start of ATI | Time to viral rebound up to 72 weeks after start of ATI, defined as the time from ATI start to first occurrence of ≥ 2,000 copies/ml. |
| Percentage of participants who remain off cART | Week 72 | Percentage of participants who remain off cART at 72 weeks after ATI start. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phenotypes characterization | From ATI start to week 72 | Different phenotypes will be characterized by the description of pVL and CD4 dynamics of each participant, and grouping according to their profile (non-rebounders, late-rebounders, post-rebound controllers, …). |
| Change in a score for ATI psychological impact | At weeks 24, 48 and at week 4 post cART resumption (or at the End of ATI visit in case of early withdrawal). | Acceptability and the psychological impact of a longer ATI will be assessed by the change in a score of a questionnaire administered at weeks 24, 48 and at week 4 post cART resumption (or at the End of ATI visit in case of early withdrawal). |
| The proportion of participants who develop symptoms compatible with acute retroviral syndrome. | From ATI start to week 72 | The proportion of participants who develop symptoms compatible with acute retroviral syndrome. |
| The proportion of participants who suppress pVL to <50 copies/ml | 24 weeks after cART resumption | The proportion of participants who suppress pVL to \<50 copies/ml 24 weeks after cART resumption |
| The proportion of participants who develop new mutations not present in the pre-cART genotype | 24 weeks after cART resumption | The proportion of participants who develop new mutations not present in the pre-cART genotype conferring clinically-significant resistance to antiretroviral drugs (out of the individuals not reaching viral re-suppression 24 weeks after cART resumption). |
| Description of participants who develop AEs related to the prime- boost regimen during this extension of ATI period. | From ATI_extension start to week 72 | Description of participants who develop AEs related to the prime-boost regimen during this extension of ATI period. |
Countries
Spain
Outcome results
None listed